Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019The Hepatitis B Therapeutics Market is forecast to Show Low Growth Throughout 2019
By: Rajesh Gunnam The current competitive landscape consists mainly of interferon therapy and nucleoside analogues. Intron A (interferon alpha 2b) and Pegasys are the two approved interferon therapies for hepatitis B therapeutics. The nucleoside analogues include Viread, Baraclude, Hepsera (adevofir), Epivir-HBV/ Zeffix (lamivudine) Pegasys was approved for the treatment of hepatitis B in 2005 in the Europe and US, in February and May respectively. It was approved in Japan in September, 2011 for the treatment of hepatitis B. Among nucleoside analogues, the US launch was witnessed for Hepsera in 2002, Baraclude in 2005, Sebivo in 2006 and Viread in 2008. Similarly, Tyzeka/Sebivo was launched in Europe in 2007, Hepsera in 2003, Viread in 2008 and Baraclude in 2006. In Japan, Hepsera was launched in 2002, Baraclude in 2006 and Viread in 2009. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The unmet need is high in hepatitis B therapeutics market. This is primarily attributed to the development of resistance to the most commonly used nucleoside therapy for the treatment of hepatitis B. The interferons also due to their high cost pose a hindrance to the patients who cannot afford it. The safety issues with all the nucleoside analogues, which have led to black box warnings being issued by the Food and Drug Administration (FDA), are also a concern for the physicians. The high unmet need can also be attributed to the poor tolerability of patients to interferon therapy. GlobalData, the industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
|